Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... AMHERST, Mass. Using a bio-mimicking analog of ... of grass, an international research team led by ... has taken a major step in developing long-sought ... to electricity for use in electronic devices. ... UMass Amherst and others at Stanford University and ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... used to kill nematodes. Nematodes are microscopic parasitic ... soil, water, and inside other plants and animals. ... high volatility or other properties promoting migration through ... contain more than 1,000 plant-parasitic nematodes. With more ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... September 30, 2014 OriginOil Inc. (OTC/QB: ... chemical-free process to clean up large quantities of water, ... Riggs Eckelberry reported on the launch of the company's ... site provided by partner STW Resources . , ... barrels per day (bpd) and achieved a 99.8% reduction ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... second can make the difference between life and death, ... sensors" that allow for faster response times from military ... NC State that will help ensure those sensors will ... Afghanistan or elsewhere. "We,ve taken a sensor material ...
... ... of 2007 and to enhance patient safety with complete part traceability, can now use ... coding, scan and software tracking of each part and batch, including all leak test, ... ...
... the pleasantness of novel odors, just like a human ... notion that smell is completely personal and culture-specific. The ... Wolfson Medical Center, argue that the perception of an ... and it is only within specific contexts that personal ...
Cached Biology Technology:InterTech Development Company UDI System Announced 2Odor pleasantness shown to be partly hard-wired 2Odor pleasantness shown to be partly hard-wired 3
(Date:10/1/2014)... to take a healthy salad up a level by ... cancer in leafy greens. , "In the long run, ... eating the salad or making a pill from the ... engineering at Case Western Reserve School of Medicine and ... breast cancer organization is funding the research with a ...
(Date:9/30/2014)... each year, but its deep-blue waters host the ... alien species, including fish, crustaceans, and algae are ... In the open-access journal Frontiers in Marine ... data from a new information system developed by ... of alien species has changed the native biodiversity ...
(Date:9/30/2014)... Ocean Health Index rates the Earth,s oceans at ... addition, for the first time, the report assessed ... national jurisdiction (high-seas areas) all critical regions ... providing sustainable food sources. , In the third ... by scientists from UC Santa Barbara,s National Center ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2Rating the planet's oceans 2Rating the planet's oceans 3
... new map of the potato genome that may lead ... help feed the world,s hungry. By sequencing and ... consortium has, for the first time, tied specific potato ... and development of potatoes may enable scientists and breeders ...
... Institute, one of the National Institutes of Health, has ... of Medicine each approximately $2.3 million a year for ... Glycosciences. Gerald Hart, Ph.D., director of biological chemistry and ... will lead these independent efforts to better understand the ...
... TORONTO, Ont., July 12, 2001--Eating nuts every day could ... according to new research from St. Michael,s Hospital and ... online by the journal Diabetes Care , a ... of Toronto Department of Nutritional Sciences; St. Michael,s Hospital ...
Cached Biology News:Johns Hopkins researchers awarded $32 million 2A 'nutty' solution to type 2 diabetes management 2
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: